long intergenic non-protein coding RNA 1097Genealiases: []
Q-omics provides the consensus-scored LINC01097 profile across patient tissues and cancer cell-line models. LINC01097 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01097 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, LINC01097 RNA expression shows 7,167 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where LINC01097 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01097 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01097 survival associations across molecular data types. LINC01097 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01097 RNA expression–survival associations across cancer types. High LINC01097 expression shows unfavorable associations in KIRP, READ, THCA and PCPG, but favorable associations in LAML and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01097 RNA expression.
This table summarizes LINC01097 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01097. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01097 shows lower tumor expression in STAD and higher tumor expression in LUAD. The LUAD box plot shows higher LINC01097 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .003).
This table shows molecular features associated with LINC01097 in patient tissues and cancer cell lines. In patient samples, LINC01097 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
